Andrea Cercek, MD, shares insight on treatment selection, the importance of molecular testing, and unanswered questions with tumor sidedness in patients with newly diagnosed metastatic colorectal cancer.
Original Article: Molecular Markers Critical to Guiding Treatment in Newly Diagnosed mCRC